A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% In Patients With Actinic Keratoses ON Non-head Locations (REGION-I)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- The Skin Centre
-
-
Western Australia
-
Victoria Park, Western Australia, Australia, 6100
- Burswood Dermatology
-
-
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- Omni Dermatology Research
-
-
Colorado
-
Denver, Colorado, United States, 80210
- Colorado Medical Research Center
-
-
Florida
-
Kissimmee, Florida, United States, 34741
- Advanced Dermatology and Cosmetic Research
-
Orange Park, Florida, United States, 32073
- Park Avenue Dermatology
-
Ormond Beach, Florida, United States, 32174
- Advanced Dermatology & Cosmetic Surgery
-
-
Georgia
-
Newnan, Georgia, United States, 30263
- Medaphase Inc
-
Snellville, Georgia, United States, 30078-3250
- Gwinnett Clinical Research Centre
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- Dermatology Center of Indiana/Indiana Clinical Trials Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health Systems
-
-
New Jersey
-
South Delran, New Jersey, United States, 08075
- Karen S. Harkaway, MD. LLC
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Academic Dermatology Associates
-
-
New York
-
Rochester, New York, United States, 14623
- Dermatology Associates of Rochester
-
-
Ohio
-
Cleveland, Ohio, United States, 44121
- University Hospitals Case Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97223
- Oregon Medical Research
-
Portland, Oregon, United States, 97239-4501
- Oregon Health and Science University
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Dermatology East
-
Goodlettsville, Tennessee, United States, 37072
- Rivergate Dermatology and Skin Care Center
-
-
Texas
-
College Station, Texas, United States, 77845
- J & S Studies, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be male or female and at least 18 years of age.
- Female patients must be of:
- Non-childbearing potential;
- Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.
- 4 to 8 AK lesions on non-head locations.
Exclusion Criteria:
- Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.
- Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.
- Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
PEP005 (ingenol mebutate) Gel
|
two day treatment
|
|
Placebo Comparator: 2
Vehicle gel
|
two day treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients With Complete Clearance of Actinic Keratosis (AKs)
Time Frame: 57 days
|
Complete clearance rate of actinic keratosis (AK) lesions defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area.
|
57 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients With Partial Clearance of Actinic Keratosis (AKs)
Time Frame: baseline and 57 days
|
Partial clearance rate of AK lesions defined as the proportion of patients with a 75% or greater reduction in the number of actinic keratosis (AK) lesions identified at baseline in the selected treatment area.
|
baseline and 57 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PEP005-014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.